论文部分内容阅读
目的 :探讨中药配合支气管动脉灌注化疗 (BAIC)治疗肺癌的疗效。方法 :中晚期非小细胞肺癌 (NSCLC) 76例 ,随机分A、B两组。A组 39例为BAIC加中药治疗组 ,B组 37例为单纯BAIC组。观察比较两组近期疗效、远期生存率、临床主要症状变化、生存质量及外周血象变化情况。结果 :治疗后稳定加有效率 (CR +PR +NC)A、B组分别为 92 31%、70 2 7% ,组间比较差异有显著性 (P <0 0 5)。 0 5、1、2年生存率A组分别为 79 4 9%、56 4 1%、51 2 8% ;B组分别为 72 97%、51 35%、2 4 32 % ;2年生存率A组优于B组 (P <0 0 5)。在改善临床症状、卡氏评分、增加体重 ,以及对治疗后外周血象变化的改善方面 ,A组患者比B组更明显。结论 :中药配合BAIC可以提高BAIC效果。
Objective: To explore the efficacy of Chinese medicine combined with bronchial arterial infusion chemotherapy (BAIC) in the treatment of lung cancer. Methods: 76 cases of advanced non-small cell lung cancer (NSCLC) were randomly divided into A and B groups. In group A, 39 patients were treated with BAIC plus Chinese medicine, and 37 patients in group B were treated with pure BAIC. Observe and compare the short-term curative effect, the long-term survival rate, the change of the main clinical symptoms, the quality of life, and the changes of peripheral blood in the two groups. RESULTS: The stable plus effective rate after treatment (CR +PR + NC) in A and B groups was 92 31% and 70 2 7%, respectively. There was a significant difference between the two groups (P < 0.05). The 5, 1 and 2 year survival rates in group A were 79 9%, 56 4 1%, and 51 2 8%, respectively; in group B, 72 97%, 51 35%, and 2432%; 2-year survival rate A. The group was superior to group B (P < 0.05). Improvements in clinical symptoms, Karnofsky score, weight gain, and improvement of peripheral blood changes after treatment were more pronounced in group A than in group B. Conclusion : Chinese medicine combined with BAIC can improve the effect of BAIC.